<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39318203</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.</ArticleTitle><Pagination><StartPage>e29927</StartPage><MedlinePgn>e29927</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29927</ELocationID><Abstract><AbstractText>EuCorVac-19 (ECV-19) is a recombinant receptor binding domain (RBD) COVID-19 vaccine that displays the RBD (derived from the SARS-CoV-2 Wuhan strain) on immunogenic liposomes. This study compares the safety and immunogenicity of ECV-19 to the COVISHIELD<sup>TM</sup> (CS) adenoviral-vectored vaccine. Interim analysis is presented of a randomized, observer-blind, immunobridging Phase 3 trial in the Philippines in 2600 subjects, with treatment and biospecimen collection between October 2022 and January 2023. Healthy male and female adults who received investigational vaccines were 18 years and older, and randomly assigned to ECV-19 (n = 2004) or CS (n = 596) groups. Immunization followed a two-injection, intramuscular regimen with 4 weeks between prime and boost vaccination. Safety endpoints were assessed in all participants and immunogenicity analysis was carried out in a subset (n = 585 in ECV-19 and n = 290 in CS groups). The primary immunological endpoints were superiority of neutralizing antibody response, as well as noninferiority in seroresponse rate (defined as a 4-fold increase in RBD antibody titers from baseline). After prime vaccination, ECV-19 had a lower incidence of local solicited adverse events (AEs) (12.0% vs. 15.8%, p &lt; 0.01), and solicited systemic AEs (13.1 vs. 17.4%, p &lt; 0.01) relative to CS. After the second injection, both ECV-19 and CS had lower overall solicited AEs (7.8% vs. 7.6%). For immunological assessment, 98% of participants had prior COVID-19 exposure (based on the presence of anti-nucleocapsid antibodies) at the time of the initial immunization, without differing baseline antibody levels or microneutralization (MN) titers against the Wuhan strain in the two groups. After prime vaccination, ECV-19 induced higher anti-RBD IgG relative to CS (1,464 vs. 355 BAU/mL, p &lt; 0.001) and higher neutralizing antibody response (1,303 vs. 494 MN titer, p &lt; 0.001). After boost vaccination, ECV-19 and CS maintained those levels of anti-RBD IgG (1367 vs. 344 BAU/mL, p &lt; 0.001) and neutralizing antibodies (1128 vs. 469 MN titer, p &lt; 0.001). ECV-19 also elicited antibodies that better neutralized the Omicron variant, compared to CS (763 vs. 373 MN titer, p &lt; 0.001). Women displayed higher responses to both vaccines than men. The ECV-19 group had a greater seroresponse rate compared to CS (83% vs. 30%, p &lt; 0.001). In summary, both ECV-19 and CS had favorable safety profiles, with ECV-19 showing diminished local and systemic solicited AE after prime immunization. ECV-19 had significantly greater immunogenicity in terms of anti-RBD IgG, neutralizing antibodies, and seroresponse rate. These data establish a relatively favorable safety and immunogenicity profile for ECV-19. The trial is registered on ClinicalTrials.gov (NCT05572879).</AbstractText><CopyrightInformation>© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lovell</LastName><ForeName>Jonathan F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-9052-884X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University at Buffalo, Buffalo, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miura</LastName><ForeName>Kazutoyo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baik</LastName><ForeName>Yeong Ok</ForeName><Initials>YO</Initials><AffiliationInfo><Affiliation>EuBiologics, R&amp;D Center, EuBiologics Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chankyu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>EuBiologics, R&amp;D Center, EuBiologics Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>YoungJin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>EuBiologics, R&amp;D Center, EuBiologics Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Her</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>EuBiologics, R&amp;D Center, EuBiologics Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jeong-Yoon</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>EuBiologics, R&amp;D Center, EuBiologics Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ylade</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Institutes of Health, University of the Philippines Manila, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee-Llacer</LastName><ForeName>Roxas</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bicol Regional Training and Teaching Hospital, Albay, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Asis</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Norzel Medical &amp; Diagnostic Clinic, Cebu City, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinidad-Aseron</LastName><ForeName>Mitzi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Perpetual Help System DALTA, Manila, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranola</LastName><ForeName>Jose Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>St John Hospital Inc, Camarines Sur, Philippines.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jesus</LastName><ForeName>Loreta Zoleta</ForeName><Initials>LZ</Initials><AffiliationInfo><Affiliation>Silang Specialists Medical Center, Cavite, Philippines.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05572879</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>EuBiologics and the Ministry of Health and Welfare</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010679" MajorTopicYN="N" Type="Geographic">Philippines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">adjuvants</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39318203</ArticleId><ArticleId IdType="doi">10.1002/jmv.29927</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Msemburi W, Karlinsky A, Knutson V, Aleshin‐Guendel S, Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID‐19 pandemic. Nature. 2023;613(7942):130‐137.</Citation></Reference><Reference><Citation>Williams BA, Jones CH, Welch V, True JM. Pandemic preparedness requires collaboration between governments, funders and pharma. Nature Med. 2023;29(12):2999‐3001.</Citation></Reference><Reference><Citation>Kumar S, Basu M, Ghosh P, Ansari A, Ghosh MK. COVID‐19: clinical status of vaccine development to date. Br J Clin Pharmacol. 2023;89(1):114‐149.</Citation></Reference><Reference><Citation>Mabrouk MT, Huang WC, Martinez‐Sobrido L, Lovell JF. Advanced materials for SARS‐CoV‐2 vaccines. Adv Mater. 2022;34(12):e2107781.</Citation></Reference><Reference><Citation>Kleanthous H, Silverman JM, Makar KW, Yoon I‐K, Jackson N, Vaughn DW. Scientific rationale for developing potent RBD‐based vaccines targeting COVID‐19. NPJ Vaccines. 2021;6(1):128.</Citation></Reference><Reference><Citation>Lovell JF, Baik YO, Choi SK, et al. Interim analysis from a phase 2 randomized trial of EuCorVac‐19: a recombinant protein SARS‐CoV‐2 RBD nanoliposome vaccine. BMC Med. 2022;20(1):462.</Citation></Reference><Reference><Citation>Lovell JF, Miura K, Baik YO, et al. One‐year antibody durability induced by EuCorVac‐19, a liposome‐displayed COVID‐19 receptor binding domain subunit vaccine, in healthy Korean subjects. Int J Infect Dis. 2024;138:73‐80.</Citation></Reference><Reference><Citation>Earle KA, Ambrosino DM, Fiore‐Gartland A, et al. Evidence for antibody as a protective correlate for COVID‐19 vaccines. Vaccine. 2021;39(32):4423‐4428.</Citation></Reference><Reference><Citation>Khoury DS, Schlub TE, Cromer D, et al. Correlates of protection, thresholds of protection, and immunobridging among persons with SARS‐CoV‐2 infection. Emerging Infect Dis. 2023;29(2):381‐388.</Citation></Reference><Reference><Citation>Lazarus R, Querton B, Corbic Ramljak I, et al. Immunogenicity and safety of an inactivated whole‐virus COVID‐19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1‐S in adults in the UK (COV‐COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect Dis. 2022;22(12):1716‐1727.</Citation></Reference><Reference><Citation>Estrada JA, Cheng C‐Y, Ku S‐Y, et al. An immunobridging study to evaluate the neutralizing antibody titer in adults immunized with two doses of either ChAdOx1‐nCov‐19 (AstraZeneca) or MVC‐COV1901. Vaccines. 2022;10(5):655.</Citation></Reference><Reference><Citation>Torales J, Cuenca‐Torres O, Barrios L, et al. An evaluation of the safety and immunogenicity of MVC‐COV1901: results of an interim analysis of a phase III, parallel group, randomized, double‐blind, active‐controlled immunobridging study in Paraguay. Vaccine. 2023;41(1):109‐118.</Citation></Reference><Reference><Citation>Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV‐19) Covid‐19 vaccine. N Engl J Med. 2021;385(25):2348‐2360.</Citation></Reference><Reference><Citation>Ghosh S, Shankar S, Chatterjee K, et al. COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline workers of Indian armed forces: interim results of VIN‐WIN cohort study. Med J Armed Forces India. 2021;77:S264‐S270.</Citation></Reference><Reference><Citation>Song JY, Choi WS, Heo JY, et al. Immunogenicity and safety of SARS‐CoV‐2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active‐controlled, observer‐blinded, phase 3 trial. EClinicalMedicine. 2023;64:102140.</Citation></Reference><Reference><Citation>Manenti A, Maggetti M, Casa E, et al. Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samples. J Med Virol. 2020;92(10):2096‐2104.</Citation></Reference><Reference><Citation>Ko GY, Lee J, Bae H, et al. Longitudinal analysis of SARS‐CoV‐2‐Specific cellular and humoral immune responses and breakthrough infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 vaccination: a prospective cohort in naive healthcare workers. Vaccines. 2023;11(10):1613.</Citation></Reference><Reference><Citation>Thuluva S, Paradkar V, Gunneri S, et al. Immunogenicity and safety of biological e's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV‐19) vaccine studied in a phase‐3, single blind, multicentre, randomized clinical trial. Hum Vaccines Immunother. 2023;19(1):2203632.</Citation></Reference><Reference><Citation>Jensen A, Stromme M, Moyassari S, et al. COVID‐19 vaccines: considering sex differences in efficacy and safety. Contemp Clin Trials. 2022;115:106700.</Citation></Reference><Reference><Citation>Mak WA, Koeleman JGM, van der Vliet M, Keuren F, Ong DSY. SARS‐CoV‐2 antibody and T cell responses one year after COVID‐19 and the booster effect of vaccination: a prospective cohort study. J Infect. 2022;84(2):171‐178.</Citation></Reference><Reference><Citation>Almendro‐Vázquez P, Chivite‐Lacaba M, Utrero‐Rico A, et al. Cellular and humoral immune responses and breakthrough infections after three SARS‐CoV‐2 mRNA vaccine doses. Front Immunol. 2022;13:981350.</Citation></Reference><Reference><Citation>Hsieh SM, Chang SC, Cheng HY, Shih SR, Lien CE. Durability and immunogenicity of neutralizing antibodies response against omicron variants after three doses of subunit SARS‐CoV‐2 vaccine MVC‐COV1901: an extension to an open‐label, dose‐escalation phase 1 study. Infect Dis Ther. 2022;11(4):1493‐1504.</Citation></Reference><Reference><Citation>Srivastava K, Carreño JM, Gleason C, et al. Kinetics and durability of humoral responses to SARS‐CoV‐2 infection and vaccination. medRxiv. 2023. doi:10.1101/2023.08.26.23294679</Citation></Reference><Reference><Citation>Chalkias S, Eder F, Essink B, et al. Safety, immunogenicity and antibody persistence of a bivalent beta‐containing booster vaccine against COVID‐19: a phase 2/3 trial. Nature Med. 2022;28(11):2388‐2397.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>